摘要
肝硬化是慢性肝病的终末阶段,其包含代偿和失代偿阶段,在晚期伴随着一系列相关并发症,如食管胃静脉曲张出血、肝性脑病、自发性细菌性腹膜炎等凶险情况。质子泵抑制剂(proton pump inhibitors,PPIs)是目前最常见的使用于胃酸相关疾病的药物之一,其在肝硬化患者中也广泛使用,但其适应证往往不明确。目前,越来越多的证据表明PPIs在肝硬化及其并发症的患者中可能会产生较严重的不良后果,因此呼吁减少不恰当的使用并尽可能缩短使用时间和剂量。目前随着证据的累积,缺乏相关的系统总结,我们在此总结最新的关于PPIs在肝硬化患者中的使用带来的后果以及未来展望。
Cirrhosis is the end stage of chronic liver disease,which consists of compensated and decompensated stages,accompanied by a series of associated complications such as gastroesophageal variceal bleeding,hepatic encephalopathy,spontaneous bacterial peritonitis,and other aggressive conditions in the late stage.Proton pump inhibitors(PPIs)are currently one of the most common drugs used in gastric acid-related diseases,and they are also widely used in patients with cirrhosis,but their indications are often unclear.There is now growing evidence that PPIs may have greater adverse outcomes in patients with cirrhosis and its complications and consequently calls for a reduction in inappropriate use and the shortest possible duration and dose.Currently,as the evidence accumulates,there is a lack of systematic summaries of the relevant findings,and we provided here a review of the latest information on the consequences of PPIs used in patients with cirrhosis and the outlook.
作者
古盼瑶
陈明锴
GU Panyao;CHEN Mingkai(Department of Gastroenterology,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《胃肠病学和肝病学杂志》
CAS
2024年第11期1566-1569,共4页
Chinese Journal of Gastroenterology and Hepatology
基金
湖北省重点研发计划项目(2020BCB007)
武汉大学人民医院2022年度交叉创新人才项目(JCRCFZ-2022-017)。
关键词
肝硬化
质子泵抑制剂
药物安全
适应证
Cirrhosis
Proton pump inhibitors
Drug safety
Indications
作者简介
第一作者:古盼瑶,在读硕士,研究方向:肝硬化的诊治。E-mail:1194975176@qq.com;通讯作者:陈明锴,博士,主任医师,教授,博士生导师,研究方向:肝硬化的诊治。E-mail:kaimingchen@163.com。
